A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of ARD-101 in Subjects At Least One Year After Bariatric Surgery
Latest Information Update: 13 Feb 2025
At a glance
- Drugs ARD-101 (Primary)
- Indications Weight gain
- Focus Therapeutic Use
- Sponsors Aardvark Therapeutics
Most Recent Events
- 12 Jun 2023 Results presented in an Aardvark Therapeutics media release.
- 16 May 2023 Status changed from active, no longer recruiting to completed.
- 11 Jan 2023 Planned End Date changed from 1 Feb 2023 to 30 Apr 2023.